glp 1 is insulin Insights into GLP-1 and secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment GLP-1R and Diabetes

Retatrutide (Triple GLP-1 + GIP + Glucagon Agonist) Retatrutide (LY3437943) is described in clinical literature as a triple hormone-receptor agonist targeting: GIPR GLP-1R Glucagon receptor (GCGR) (New England Journal of Medicine) Why adding glucagon receptor activity is scientifically interesting and important Glucagon receptor signalling is associated with: increased energy expenditure pathways hepatic metabolic effects potentially different body-composition dynamics compared to GLP-1only approaches Glucagon receptivity means that muscle may be stimulated through increased glucose utilisation in muscle cells

Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency

7 GLP-1s have the potential to transform the way obesity and diabetes are treated

Liraglutide Versus Glimepiride Monotherapy for Type 2 Diabetes (LEAD-3 Mono): A Randomised, 52-Week, Phase III, Double-Blind, Parallel-Treatment Trial